Demographics and treatment characteristics of all study patients
| All patients | |
| n=282 | |
| Male (%) | 79.8% |
| Age (median, IQR) | 36 (26–55) |
| Mechanism (%) | |
| Blunt | 55.3% |
| Penetrating injury | 44.7% |
| Comorbidities | |
| Active cancer | 1.4% |
| Liver disease | 2.1% |
| History of VTE | 1.4% |
| ISS (median, IQR) | 17 (10–26) |
| BMI (median, IQR) | 24.7 (22–28.7) |
| ICU length of stay (days; median, IQR) | 4 (2 - 8) |
| Hospital length of stay (days; median, IQR) | 10 (6–19) |
| Admission INR (median, IQR) | 1.1 (1.0–1.2) |
| Creatinine clearance (median, IQR) | 123 (96–164) |
| First enoxaparin dose | |
| 30 mg two times per day | 95.7% |
| 40 mg two times per day | 3.6% |
| 60 mg two times per day | 0.7% |
| First anti-Xa level (median, IQR) | 0.18 (0.12–0.24) |
| First anti-Xa level (%) | |
| Subtherapeutic | 56.6% |
| Therapeutic | 42.7% |
| Supratherapeutic | 0.7% |
| Total anti-Xa levels collected (median, IQR) | 1 (1-2) |
| Dose modifications made (median, IQR) | 0 (0–1) |
| Final enoxaparin dose (%) | |
| 30 mg two times per day | 58.4% |
| 40 mg two times per day | 30.6% |
| 60 mg two times per day | 8.9% |
| 80 mg two times per day | 1.4% |
| 100 mg two times per day | 0.7% |
| Reached goal anti-Xa level (%) | 70.8% |
| Major bleeding (%) | 2.1% |
| Venous thromboembolic events (%) | 9.9% |
| Mortality (%) | 1.1% |
BMI, body mass index; ICU, intensive care unit; INR, international normalized ratio; IQR, interquartile range; ISS, Injury Severity Score; VTE, venous thromboembolism.